HENGRUI PHARMA (01276.HK): SHR-7012 Injection Receives Clinical Trial Approval for Treating Cutaneous Lupus Erythematosus

NewTimeSpace News: On 20 August 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 01276) disclosed through an overseas regulatory announcement that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) for SHR-7012 injection, and clinical trials will commence shortly. The clinical trial application for SHR-7012 injection was accepted on 21 May 2026 (acceptance number CXSL2600557), with the intended indication of cutaneous lupus erythematosus (CLE).

SHR-7012 injection is an innovative drug independently developed by the company; according to research, no drug targeting the same target has been approved for marketing domestically or internationally to date. As of now, the cumulative R&D investment in the SHR-7012 injection project is approximately RMB 25.5 million (unaudited). Following clinical trial approval, the drug must undergo clinical trials and pass the review and approval of the NMPA before it can be manufactured and marketed; the cycle from drug development and clinical trial application through to production is long and involves multiple stages, and drug development through to marketing is susceptible to uncertainty factors.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.